 |
|
Treatment With An Antipsychotic Drug Found To Cause Changes In Metabolism Earlier Than Expected
April 08, 2008New study in male rats reveals increases in problems associated with metabolic syndrome
SAN DIEGO, CA - Schizophrenia is a complex type of psychotic mental illness characterized by thoughts that are uncoupled from reality. Huge gains in the effective treatment of individuals with the disease began in the 1950s with the development of the first generation of antipsychotic drugs. The medications allowed physicians to treat the "positive" effects of the illness (delusions and hallucinations) and, to a lesser extent, the "negative" symptoms (apathy). The second generation of antipsychotics - known as atypical antipsychotics (AAP) - began in 1990. These newer medicines have proven as effective in treating the positive aspects of the disease and more effective in combating the negative ones.
As is the case with nearly all medications, antipsychotics have side affects, including weight gain and some other risk factors of metabolic syndrome, which puts an individual at greater risk of heart disease and type 2 diabetes. Physicians are concerned that these side effects may cause their patients to stop taking their medicine.
A team of French researchers has found, in an animal model, that the consumption of at least one atypical antipsychotic exhibits some of the risks for metabolic syndrome in humans. This model allows researchers to explore the sequence of early metabolic events that may result from atypical medications.
Presentation at the 121st Annual Meeting of the American Physiological Society
Montserrat Victoriano, Gilles Fromentin, Jean-Francois Huneau, and Dominique Hermier of the Department of Human Nutrition, INRA, Paris, France; and Renaud de Beaurepaire, Department of Psychopharmacology, Hospital Paul Guiraud, Villejuif, France, are the researchers. They have conducted a study entitled Energy Metabolism Disturbances Induced by Antipsychotic Treatment in a Rat Model. Dr. Hermier will present the team's findings at the 121st annual meeting of the American Physiological Society (APS; www.the-APS.org/press), part of the Experimental Biology 2008 scientific conference.
Summary of the Study
The researchers had previously developed a model for antipsychotic-induced weight gain in the male rat, which allowed them to clearly distinguish between those antipsychotic drugs that produce some weight gain, moderate weight gain or no gain at all. These distinctions corresponded to the response in humans. Their latest study is built on these findings.
In the latest study they used 18 male rats which were randomly assigned to one of three groups: (1) those receiving the conventional antipsychotic drug haloperidol (HA); (2) those receiving the atypical antipsychotic drug olanzapine (OL); or (3) the control (CO) group which did not receive either drug. The medicines were given in food for a period of six weeks. Female rats were excluded to eliminate bias in the study since antipsychotic-induced weight gain in female rodents is likely related to an interaction of the drugs with estrogens.
Testing after four weeks found that the concentration of blood sugar (as glucose) was higher in OL rats (0.87 g/l) than in CO rats (0.75 g/l) and the levels increased more rapidly after a glucose meal. Testing six weeks later found fasting blood sugar levels continued to rise in OL rats (1.46 g/l vs. 1.25 g/l in CO rats) while the level of lipids (fats) in the blood was similar for both groups. Although there was no difference in body weight gain or food intake, the proportion of fat stored in the abdominal cavity was higher in OL rats (1.63%) vs. CO rats (1.44%).
The HA rats did not vary in any way with the control group at any time. They exhibited a lower blood sugar level after a glucose meal and a lower proportion of intraabdominal fat store (1.44%) than OL rats.
Conclusions
Senior study author Dominique Hermier said, "Based on these findings we concluded that male rats treated with olanzapine experienced an early disruption of energy metabolism. This was a result of the fat tissue we observed and the impairment in blood sugar regulation which are both associated with metabolic syndrome and subsequent risk of diabetes."
She added, "Atypical medications like olanzapine are of tremendous value in treating individuals with certain kinds of mental illness. Our hope is that through discoveries such as this one, such life-enhancing medicines can be further optimized."
The American Physiological Society (APS)
A team of French researchers has found, in an animal model, that the consumption of at least one atypical antipsychotic exhibits some of the risks for metabolic syndrome in humans. This model allows researchers to explore the sequence of early metabolic events that may result from atypical medications.
Presentation at the 121st Annual Meeting of the American Physiological Society
Montserrat Victoriano, Gilles Fromentin, Jean-Francois Huneau, and Dominique Hermier of the Department of Human Nutrition, INRA, Paris, France; and Renaud de Beaurepaire, Department of Psychopharmacology, Hospital Paul Guiraud, Villejuif, France, are the researchers. They have conducted a study entitled Energy Metabolism Disturbances Induced by Antipsychotic Treatment in a Rat Model. Dr. Hermier will present the team's findings at the 121st annual meeting of the American Physiological Society (APS; www.the-APS.org/press), part of the Experimental Biology 2008 scientific conference.
Summary of the Study
The researchers had previously developed a model for antipsychotic-induced weight gain in the male rat, which allowed them to clearly distinguish between those antipsychotic drugs that produce some weight gain, moderate weight gain or no gain at all. These distinctions corresponded to the response in humans. Their latest study is built on these findings.
In the latest study they used 18 male rats which were randomly assigned to one of three groups: (1) those receiving the conventional antipsychotic drug haloperidol (HA); (2) those receiving the atypical antipsychotic drug olanzapine (OL); or (3) the control (CO) group which did not receive either drug. The medicines were given in food for a period of six weeks. Female rats were excluded to eliminate bias in the study since antipsychotic-induced weight gain in female rodents is likely related to an interaction of the drugs with estrogens.
Testing after four weeks found that the concentration of blood sugar (as glucose) was higher in OL rats (0.87 g/l) than in CO rats (0.75 g/l) and the levels increased more rapidly after a glucose meal. Testing six weeks later found fasting blood sugar levels continued to rise in OL rats (1.46 g/l vs. 1.25 g/l in CO rats) while the level of lipids (fats) in the blood was similar for both groups. Although there was no difference in body weight gain or food intake, the proportion of fat stored in the abdominal cavity was higher in OL rats (1.63%) vs. CO rats (1.44%).
The HA rats did not vary in any way with the control group at any time. They exhibited a lower blood sugar level after a glucose meal and a lower proportion of intraabdominal fat store (1.44%) than OL rats.
Conclusions
Senior study author Dominique Hermier said, "Based on these findings we concluded that male rats treated with olanzapine experienced an early disruption of energy metabolism. This was a result of the fat tissue we observed and the impairment in blood sugar regulation which are both associated with metabolic syndrome and subsequent risk of diabetes."
She added, "Atypical medications like olanzapine are of tremendous value in treating individuals with certain kinds of mental illness. Our hope is that through discoveries such as this one, such life-enhancing medicines can be further optimized."
The American Physiological Society (APS)
Antipsychotic Drug Current Events and Antipsychotic Drug News RSSAnti-psychotic drugs could help fight cancer
The observation that people taking medication for schizophrenia have lower cancer rates than other people has prompted new research revealing that anti-psychotic drugs could help treat some major cancers.
Innappropriate drug prescriptions wasting millions, raising health risks
A recent study in Oregon suggests that drugs designed for treating the most severe mental illnesses are often prescribed at inappropriately low doses and at considerable expense, for use in conditions where their benefit has not been established.
Pitt research identifies new target in brain for treating schizophrenia
Research from the University of Pittsburgh could expand the options for controlling schizophrenia by identifying a brain region that responds to more than one type of antipsychotic drug.
Risks and benefits of antipsychotics in children and adolescents
Many of the psychiatric disorders observed in adults have their onset in childhood or adolescence. In fact some studies show that at least 20% of children and adolescents will fulfil a diagnostic criterion for a mental disorder before reaching adulthood.
Short-term use of antipsychotics in older adults with dementia linked to serious adverse events
Older adults with dementia who receive short-term courses of antipsychotic medications are more likely to be hospitalized or die than those who do not take the drugs, according to a report in the May 26 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Hopkins researchers discover new link to schizophrenia
Neuroscientists at Johns Hopkins have discovered that mice lacking an enzyme that contributes to Alzheimer disease exhibit a number of schizophrenia-like behaviors.
Common treatment for methamphetamine overdose may damage brain cells
A common antipsychotic drug used in emergency rooms to treat methamphetamine overdose damages nerve cells in an area of the brain known to regulate movement, a new study shows.
Antipsychotic drug may block addiction, UIC researchers find
Researchers at the University of Illinois at Chicago have discovered that a long-approved oral antipsychotic drug can stop the addictive properties of opioid painkillers in mice.
Atypical antipsychotic drugs for dementia may be associated with small increased risk of death
Patients with dementia who took atypical antipsychotic drugs had a slightly increased risk of death compared to patients who took placebo, according to a meta-analysis published in the October 19 issue of JAMA.
Top Psychiatry Researchers Honoured with International Career Development Award
American Psychiatric Association and AstraZeneca Reward '2004 Young Minds in Psychiatry' Winners
More Antipsychotic Drug Current Events and Antipsychotic Drug News Articles
 |
Antipsychotics and Mood Stabilizers: Stahl's Essential Psychopharmacology, 3rd edition (Essential Psychopharmacology Series) by Stephen M. Stahl (Author) Relying upon the best-selling third edition of Stahl's Essential Psychopharmacology, Dr. Stephen M. Stahl has revised chapters covering antipsychotics and mood stabilizers for this third edition of Antipsychotics and Mood Stabilizers. More than one-third longer than the previous edition, Antipsychotics and Mood Stabilizers is essential reading for professionals treating psychosis and students learning the mechanisms of drug reactions. This updated edition includes advances in neurobiology and recent clinical developments to explain the concepts underlying drug treatment of psychiatric disorders. The fully revised text is complemented by many new illustrations and enhanced to reflect new knowledge and topics not covered in the previous edition. Intended as a primer text covering all... |
 |
Atypical Antipsychotics and the Spectrum Anxiety Disorders - A Video Symposium Also With: William Glazer M.D. (Primary Contributor), Mark B. Hamner M.D. (Primary Contributor), Prakash S. Masand M.D. (Primary Contributor) Current profiles indicate that U.S. clinicians prescribe a substantial amount of atypical antipsychotic medications of label, i.e. for non-schizophrenic conditions. The pharmacologic profile of the new generation medications, including clozapine, risperidone, olanzapine, quetiapine and ziprasidone, would support such use but are there studies showing clinical efficacy ni off label disease states? In particular, anxiety spectrum disorders, such as Post Traumatic Stress Disorder, Obsessive Compulsive Disorder and Attention Deficit Hyperactivity Disorder, have been shown to respond to treatment with the atypical antipsychotic agents. This PsychLink will explore this phenomenon ad present the therapeutic basis for such practice. |
 |
Promoting Wellness: Schizophrenia (Online Tutorial for Institutions) by Adrianne Avillion and Mary Dreher, Educational Global Technologies, Inc. The goal of the online tutorial Promoting Wellness: Schizophrenia is to help healthcare professionals recognize this disorder and its impact on clients, families, and the community, and to promote treatment strategies that enhance the health and wellness of clients dealing with this disorder. This online tutorial is approved for continuing education. |
 |
Essential Psychopharmacology of Antipsychotics and Mood Stabilizers (Essential Psychopharmacology Series) by Stephen M. Stahl (Author), Nancy Munter (Illustrator) Drawn from the best-selling second edition of Essential Psychopharmacology, Steve Stahl has revised and updated the chapters covering antipsychotics and mood stabilizers in this separate volume. This new book covers the many dimensions of psychosis, particularly as associated with schizophrenia, and examines the role of dopamine in psychosis along with the various theories about the causes, pathophysiology, and treatment of schizophrenia. New material includes discussion of a promising new agent, aripiprazole, the first in a new class of dopamine stabilizers; the use of anticonvulsant agents to treat manic psychosis as well as being used as adjuncts to more traditional antipsychotic treatments for psychosis and schizophrenia; and the newest atypical antipsychotic ziprasidone. CME... |
 |
The Essential Guide to Psychiatric Drugs: Includes The Most Recent Information On: Antidepressants, Tranquilizers and Antianxiety Drugs, Antipsychotics, ... and Withdrawal Symptoms, and Much, Much More by Jack M. Gorman M.D. (Author) Informative, accessible, and easy to use, The Essential Guide to Psychiatric Drugs has become a classic and indispensable resource for the layperson and professional alike. With detailed descriptions of all the psychiatric medications available today, including their uses, side-effects, cost, dosage, and more, consumers can take an active role in their mental health and know what to expect from specific drugs. Completely updated to include the latest drugs and research, this invaluable guide also includes: -Information on six new antidepressants similar to Prozac, including Paxil, Effexor, and Wellbutrin -Revolutionary new drug treatments for nicotine addiction -Depakote, a new treatment for anxiety disorders -And much more! |
 |
Psychopharmacology of Antipsychotics by Stephen M. Stahl (Author) (Martin Dunitz) Univ. of California, San Diego. Pocket-sized text presents a series of visual lessons on the antipsychotic drugs. Figures and diagrams are based on the textbook Essential Psychopharmacology, c1996. Color illustrations. For clinicians and students. Trim size: 8.25 x 5.75 inches. Softcover. |
|
Antipsychotic Drugs, Pharmacodynamics and Pharmacokinetics: Proceedings of the International Symposium Held in Wenner-Gren Center, Stockholm, Septembe ... Library of Science, Technology, Engin) by Goran Sedvall (Other Contributor) | |
 |
Antipsychotic Drugs and Their Side-Effects (Neuroscience Perspectives) by Thomas R.E. Barnes (Editor), Peter Jenner (Editor) In line with other volumes in the Neuroscience Perspectives Series, this volume covers the background, pharmacology, molecular biology, and biochemistry of antipsychotic drugs, together with an overview assessment of the therapeutic considerations. Over the past 40 years, the effectiveness of conventional neuroleptic agents for psychotic illness has been offset by a wide range of adverse side-effects, including motor side-effects like parkinsonism. Studies show that lowering doses may still produce the antipsychotic effect while lessening the risk of side-effects. As all available antispychotic drugs are able to block dopamine, specifically D2 receptors, doses below the threshold level for producing acute motor disorder can still be therapeutically effective. With the identification and... |
|
Tardive Dykinesia : American Psychiatric Association Task Force Report 18 : Report of the American Psychiatric Association Task Force on Late Neurological Effects on Antipsychotic Drugs by Ross J. Et al Baldessarini (Author) | |
|
Antipsychotic Drugs: An entry from Gale's Gale Encyclopedia of Medicine, 3rd ed. by Samuel, PharmD Uretsky (Author), Rebecca, PhD Frey (Author) This digital document is an article from Gale Encyclopedia of Medicine, 3rd ed., brought to you by Gale®, a part of Cengage Learning, a world leader in e-research and educational publishing for libraries, schools and businesses. The length of the article is 1137 words. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. The third edition of this authoritative, comprehensive, in-depth medical guide features information on medical topics in language accessible to adult laypersons. Disease/disorder articles typically cover definition; description; causes and symptoms; diagnosis; treatments; prevention; and more. Test/treatment articles typically cover definition; purposes;... |
| © 2009 BrightSurf.com |